Tag Archives: surveillance

Surgery associated with better survival for patients with advanced laryngeal cancer

Approximately 11,000 to 13,000 cases of laryngeal cancer are diagnosed each year and squamous cell carcinoma accounts for the vast majority of these tumors. Prior to 1991, total surgical removal of the larynx with postoperative radiation was the standard of care for advanced cancer. Since then, chemoradiation has become increasingly popular treatment because it can preserve the larynx. The authors evaluated survival outcomes for surgical vs. …

U.S. cervical cancer rates higher than previously reported, especially among older women, African-American women

Previous research finds an age-standardized rate of about 12 cases of cervical cancer per 100,000 women in the United States, with the incidence reaching a peak at age 40-44 and then leveling off. However, these estimates included women who had hysterectomies in which the lower part of the uterus, the cervix, was removed. By excluding these women, who are no longer at risk of developing this cancer, from their analysis, the researchers calculated a rate of 18.6 cases of cervical cancer per 100,000 women. They found the incidence increased steadily with age and peaked at a higher rate and at an older age, specifically in women 65-69 years old…

Diagnosing physicians influence treatment decisions for prostate cancer patients, study finds — ScienceDaily

The findings, published in JAMA Internal Medicine, sought to examine why active surveillance, a management program for low-risk disease, which includes repeat PSAs, prostate exams and biopsies, is underused in this patient population. According to the American Cancer Society, 233,000 new cases of prostate cancer will be diagnosed this year, making it the most common non-skin cancer in men…

Marginal life expectancy benefit from contralateral prophylactic mastectomy — ScienceDaily

To assess the survival benefit of CPM, Pamela R. Portschy, of the Department of Surgery, University of Minnesota, Minneapolis, and colleagues, developed a model simulating survival outcomes of CPM or no CPM for women with newly diagnosed stage I or II breast cancer, using data from the Surveillance, Epidemiology, and End Results (SEER) registry and large meta-analyses. Survival benefit projections were made for women by age (40, 50, or 60 years), breast cancer stage (I or II), and estrogen receptor (ER) status (positive or negative). Women with BRCA mutations were excluded from the analysis because they have a much higher risk of developing contralateral breast cancer. …